RecruitingGeographic Atrophy Secondary to Age-related Macular Degeneration
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
Eligible age
55+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed annually for up to 5 years.
Sponsor: Complement Therapeutics
You may qualify if…
- ✓ Meet protocol-defined age eligibility
- ✓ Have bilateral geographic atrophy secondary to AMD, confirmed by the Reading Center
- ✓ Meet baseline lesion size requirements, as assessed by fundus autofluorescence imaging
- ✓ Meet best-corrected visual acuity and low-luminance visual acuity criteria, as measured by ETDRS charts
- ✓ Meet retinal sensitivity criteria, as measured by microperimetry
- ✓ Have sufficient fellow-eye visual function to ensure navigational vision
- ✓ Have adequate historical SD-OCT imaging available for longitudinal assessment
- ✓ Meet reproductive status and contraception requirements, where applicable
You may not qualify if…
- ✕ Macular atrophy or retinal disease not attributable to AMD
- ✕ Evidence of current or prior choroidal neovascularization (wet AMD)
- ✕ Prior intraocular, macular, or retinal surgery or laser treatment that may confound assessments
- ✕ Prior AMD-directed or intravitreal therapy in the study eye, except permitted supplements
- ✕ Prior exposure to complement inhibitor therapies
- ✕ Ocular conditions, infections, inflammation, or media opacities that interfere with safety or retinal imaging
- ✕ Uncontrolled glaucoma, diabetic retinopathy, or clinically significant refractive error
- ✕ Aphakia or compromised posterior capsule, except as permitted by protocol
Where it's recruiting
Source: ClinicalTrials.gov · NCT07392255 · last updated 2026-06-22